Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesNSE:SAILIFE +2.51%18 Return-on-Tangible-Equity is 16.83% as of Mar. 2026, which is 87% above its 10-year median of 9.01. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 71.87% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sai Life Sciences's annualized net income for the quarter that ended in Mar. 2026 was ₹4,169 Mil. Sai Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹24,776 Mil. Therefore, Sai Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 16.83%.
The historical rank and industry rank for Sai Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:SAILIFE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.72 Med: 9.01 Max: 15.27
Current: 15.27
During the past 5 years, Sai Life Sciences's highest Return-on-Tangible-Equity was 15.27%. The lowest was 0.72%. And the median was 9.01%.
NSE:SAILIFE's Return-on-Tangible-Equity is ranked better than 71.87% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs NSE:SAILIFE: 15.27
Sai Life Sciences (NSE:SAILIFE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sai Life Sciences Return-on-Tangible-Equity Related Terms
Sai Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.83% mean?
Sai Life Sciences (NSE:SAILIFE) has a Return-on-Tangible-Equity of 16.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sai Life Sciences and its competitors. This is 87% above median its historical median of 9.01. Over the past decade, Sai Life Sciences' Return-on-Tangible-Equity has ranged from 0.72 to 15.27. According to the industry distribution chart, Sai Life Sciences ranks #54 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 28.1%.
Is Sai Life Sciences' Return-on-Tangible-Equity too high?
Sai Life Sciences' current Return-on-Tangible-Equity of 16.83% is 87% above median its 10-year median of 9.01. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 15.27. Based on the distribution chart, Sai Life Sciences ranks #54 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #54 out of 192 companies for Return-on-Tangible-Equity. This puts Sai Life Sciences in the upper half of its industry. Historically, Sai Life Sciences' own Return-on-Tangible-Equity has ranged from 0.72 to 15.27 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current Return-on-Tangible-Equity is 16.83%, which is 87% above median its own 10-year median of 9.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Return-on-Tangible-Equity of 16.83%. The current Return-on-Tangible-Equity is 16.83%, which is 87% above median its 10-year median of 9.01. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Return-on-Tangible-Equity is 16.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
